Table 1.
Baseline characteristics of primary and SLE-related AIHA patients
| Primary (n = 19) | SLE-related (n = 18) | p value | |
|---|---|---|---|
| Age, years | 57 ± 16 | 39 ± 20 | 0.004※ |
| Female gender | 9 (47.4) | 13 (72.2) | 0.124 |
| Hemoglobin, g/dl | 6.9 ± 1.9 | 7.9 ± 2.6 | 0.199 |
| Reticulocyte count,% | 12.2 ± 8.6 | 6.8 ± 7.1 | 0.045§ |
| Platelet count, ×109/L | 166 ± 104 | 171 ± 101 | 0.874 |
| Total bilirubin, mg/dl | 3.1 ± 1.7 | 1.4 ± 1.4 | 0.002※ |
| Unconjugated bilirubin, mg/dl | 1.9 ± 1.3 | 0.7 ± 0.7 | 0.002※ |
| Lactate dehydrogenase, U/L | 622 (387-1154) | 361 (265-498) | 0.004※ |
| Complements | |||
| C3, mg/dl | 73.6 ± 31.8 | 56.5 ± 36.7 | 0.296 |
| C4, mg/dl | 9.4 ± 5.5 | 7.2 ± 6.7 | 0.451 |
| Direct antiglobulin test | |||
| Anti-IgG (+) | 19 (100) | 18 (100) | 1.000 |
| Anti-C3d (+) | 15 (78.9) | 17 (94.4) | 0.370 |
| Autoantibodies | |||
| Antinuclear antibody (+) | 13 (68.4) | 17 (94.4) | 0.110 |
| Anticardiolipin antibody (+) | 2 (10.5) | 9 (50.0) | 0.009※ |
| Indirect antiglobulin test, titer | 8 (1-32) | 2 (1-4) | 0.169 |
| Peripheral lymphocyte phenotype | |||
| CD3+CD4+,% | 36 ± 20 | 34 ± 9 | 0.804 |
| CD3+CD8+,% | 33 ± 18 | 40 ± 11 | 0.294 |
| CD16+CD56+,% | 7 ± 5 | 7 ± 4 | 0.984 |
| CD19+,% | 21 ± 12 | 17 ± 7 | 0.365 |
Data are presented as mean ± SD, as number (percentage), or as median (interquartile range).
§p <0.05, ※p <0.01.